Afleveringen
-
Zijn er afleveringen die ontbreken?
-
Within this podcast, Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy, Dr. Howard Kaufman and Dr. Anna C. Pavlick examine the patient and tumor characteristics that may make a patient with advanced melanoma a good candidate for oncolytic viral therapy with or without a checkpoint inhibitor.
-
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. Theses rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in the management of newly diagnosed PTCL.
To earn CME credit, follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-updates-in-newly-diagnosed-ptcl
Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_updates-in-newlydiagnosed-ptcl.pdf
-
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast expert clinicians will discuss antibody-drug conjugates in PTCL.
To earn CME Credit, please follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-antibody-drug-conjugates-in-ptcl
Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_antibodydrug-conjugates-in-ptcl.pdf
-
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss options for managing relapsed/refractory PTCL.
To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-options-for-relapsed-refractory-ptcl
-
Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in diagnosis of PTCL and the role of CD30.
To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-updates-in-diagnosis-of-ptcl-and-the-role-of-cd30
